In addition, the platform is composed of two large screens, a touch screen control panel and a viewing screen, for enhanced ease and comfort of use and also offers a new range of optimised probes, including a new high frequency abdominal C9-2X probe.
With high resolution image quality optimized for each clinical application, Aixplorer Mach 30 incorporates SuperSonic Imagine's innovative modes, which are faster and more powerful thanks to the new platform. Thus, a new generation of ShearWave Elastography (SWE PLUS) allowing the stiffness of tissues to be viewed and measured in real-time on a color map has been significantly enhanced in terms of acquisition speed and examination depth. The performance of the B mode is setting new imaging standards, with the addition of the new probes on the Mach 30.
Aixplorer Mach 30 will be officially unveiled at upcoming conferences in France and abroad, a list of which can be found on supersonicimagine.com as well as the launch video.
NB: Aixplorer Mach 30 is pending 510k FDA and CE mark.
About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company that specialises in medical imaging. The company designs, develops and markets a revolutionary ultrasound platform, Aixplorer®, which uses UltraFast™ technology that can acquire images around 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler technology, Angio PL.U.S – PLanewave UltraSensitive™ Imaging and, more recently, TriVu. ShearWave Elastography allows physicians to visualise and analyse the stiffness of tissue in real-time using a reliable, reproducible and non-invasive procedure. This is an important parameter in diagnosing potentially malignant lesions or other diseased tissue. As of today, over 300 publications have demonstrated the value of SWE in the care of patients with a wide range of diseases. The latest innovation, Angio PL.U.S, provides a higher level of microvascular imaging through significantly improved colour sensitivity and spatial resolution, while maintaining exceptional 2D image quality. SuperSonic Imagine has been granted regulatory clearances for the commercialisation of Aixplorer® on the main markets. Since April 2014, the SuperSonic Imagine company has been listed on Euronext (symbol: SSI).
Back to HCB News
